 CAMBRIDGE, Mass. SALISBURY, England--BUSINESS WIRE--KalVista Pharmaceuticals, Inc. NASDAQ: KALV, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the oral presentation of clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema HAE at the 12th C1-Inhibitor Deficiency Angioedema Workshop. Our goal is to provide the best outcome for HAE patients 